Literature DB >> 28119439

Successful treatment of tumour-induced osteomalacia after resection of an oral peripheral ossifying fibroma.

Mark Anthony Santiago Sandoval1,2, Majorie Amoroto Palermo2, Ryner Carrillo3, Rafael Bundoc4, Jose Ma Carnate5, Romelito Jose Galsim6.   

Abstract

Tumour-induced osteomalacia is a paraneoplastic syndrome wherein bone is affected by a hormone from a tumour that causes renal phosphate wasting and hypophosphataemia. Here, we present the case of a 31-year-old man who has been suffering from generalised bone pains and a spine deformity that led to loss of height. Pertinent findings are low serum phosphorus, low vitamin D and decreased bone mineral density. These findings led to a diagnosis of osteomalacia. However, the finding of an oral mass raised some questions as to what role it plays in the patient's disease. It was suspected that the oral mass (fibroma) was producing a hormone that led to renal phosphate wasting, hypophosphataemia and then osteomalacia. This hypothesis was proven after surgical removal of the mass led to normalisation of the metabolic derangements and eventually led to a resolution of the bone pains. 2017 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2017        PMID: 28119439      PMCID: PMC5278335          DOI: 10.1136/bcr-2016-218637

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

Review 1.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

Review 2.  Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature.

Authors:  Yan Jiang; Wei-bo Xia; Xiao-ping Xing; Barbara C Silva; Mei Li; Ou Wang; Hua-bing Zhang; Fang Li; Hong-li Jing; Ding-romg Zhong; Jin Jin; Peng Gao; Lian Zhou; Fang Qi; Wei Yu; John P Bilezikian; Xun-wu Meng
Journal:  J Bone Miner Res       Date:  2012-09       Impact factor: 6.741

Review 3.  Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease.

Authors:  L Darryl Quarles
Journal:  Exp Cell Res       Date:  2012-03-07       Impact factor: 3.905

4.  Phosphate metabolism and vitamin D.

Authors:  Seiji Fukumoto
Journal:  Bonekey Rep       Date:  2014-02-05

5.  Determination of the elimination half-life of fibroblast growth factor-23.

Authors:  Azarmindokht Khosravi; Carolee M Cutler; Marilyn H Kelly; Richard Chang; Richard E Royal; Richard M Sherry; Felasfa M Wodajo; Neal S Fedarko; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2007-03-20       Impact factor: 5.958

Review 6.  Regulation and function of the FGF23/klotho endocrine pathways.

Authors:  Aline Martin; Valentin David; L Darryl Quarles
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

7.  Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.

Authors:  T Shimada; S Mizutani; T Muto; T Yoneya; R Hino; S Takeda; Y Takeuchi; T Fujita; S Fukumoto; T Yamashita
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

Review 8.  Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

9.  Surgical treatment of tumor-induced osteomalacia: a retrospective review of 40 cases with extremity tumors.

Authors:  Zhi-jian Sun; Jin Jin; Gui-xing Qiu; Peng Gao; Yong Liu
Journal:  BMC Musculoskelet Disord       Date:  2015-02-26       Impact factor: 2.362

10.  Renal phosphate handling: Physiology.

Authors:  Narayan Prasad; Dharmendra Bhadauria
Journal:  Indian J Endocrinol Metab       Date:  2013-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.